Comparing the current results to its competitors, Better Therapeutics Inc reported Revenue decrease in the 3 quarter 2023 year on year by 0 %, despite the revenue increase by the most of its competitors of 6.99 %, recorded in the same quarter.
Better Therapeutics Inc , slower than the average decrease reported by the company's competitors of -13.01 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -13.01 %
March 14, 2024
:Better Therapeutics, Inc. (NASDAQ: BTTX) has announced its intention to pursue strategic alternatives and initiate the process of delisting from the Nasdaq Stock Market. At a special board meeting held on Wednesday evening, March 13, 2024, the decision was made to terminate employees and explore various options, including assignment for the benefit of creditors as well as a potential wind-down of the company.The Company acknowledges that its securities are currently subject to delisting from the Nasdaq Stock Market, with the reasons for delisting remaining undisclosed. However, this move towards strategic alternatives and delisting suggests a significant shift in the company s future direction. Better The...
February 20, 2024
San Francisco-based company Better Therapeutics Inc. (NASDAQ: BTTX), known for its pioneering work in developing prescription digital therapeutics (PDTs) for cardiometabolic diseases, has achieved a significant milestone. The United States Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Better Therapeutics innovative Cognitive Behavioral Therapy (CBT) platform aimed at effectively treating adults with metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH.Breakthrough Device Designation for Enhanced Treatment:The coveted Breakthrough Device Designation for Better Therapeutics CBT platform highlights its potential to revolutionize the treatment l...
January 17, 2024
In today s ever-evolving healthcare landscape, the role of digital therapeutics is gaining significant momentum. These innovative technological int...
Euda Health Holdings Limited operates as a digital health platform that facilitates access to healthcare services. They offer a range of online health consultations and concierge services, enabling users to connect with healthcare professionals and receive personalized medical advice and treatment. Their business model focuses on leveraging technology to streamline the healthcare experience and improve access to quality care for individuals seeking medical assistance.
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
Editas Medicine Inc.'s business model revolves around developing and commercializing transformative genome editing technologies to treat serious diseases.
Sources:
Better Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Better Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
